Koers Bayer Aktiengesellschaft Other OTC
Aandelen
BAYRY
US0727303028
Farmaceutische producten
Omzet 2024 * | 47,09 mld. 50,39 mld. | Omzet 2025 * | 47,95 mld. 51,31 mld. | Marktkapitalisatie | 26,87 mld. 28,75 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 2,08 mld. 2,23 mld. | Nettowinst (verlies) 2025 * | 3,17 mld. 3,39 mld. | EV/omzet 2024 * | 1,27 x |
Nettoschuld 2024 * | 33,1 mld. 35,42 mld. | Nettoschuld 2025 * | 29,67 mld. 31,75 mld. | EV/omzet 2025 * | 1,18 x |
K/w-verhouding 2024 * |
12,5
x | K/w-verhouding 2025 * |
8,41
x | Werknemers | - |
Dividendrendement 2024 * |
0,4% | Dividendrendement 2025 * |
0,85% | Vrij verhandelbaar | 99,97% |
Recentste transcriptie over Bayer Aktiengesellschaft
Managers | Titel | Leeftijd | Van |
---|---|---|---|
William Anderson
CEO | Chief Executive Officer | 57 | 01-04-23 |
Director of Finance/CFO | 55 | 26-04-18 | |
Bijoy Sagar
CTO | Chief Tech/Sci/R&D Officer | 55 | 01-04-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Colleen Goggins
BRD | Director/Board Member | 68 | 01-04-17 |
Director/Board Member | 68 | 01-04-17 | |
Alberto Weisser
BRD | Director/Board Member | 67 | 01-04-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+33,25% | 699 mld. | |
+26,43% | 571 mld. | |
-3,55% | 364 mld. | |
+18,16% | 326 mld. | |
+4,36% | 286 mld. | |
+14,75% | 236 mld. | |
+4,93% | 198 mld. | |
-10,18% | 194 mld. | |
-3,69% | 149 mld. |